Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

Aims/hypothesisWe aimed to describe the shape of observed relationships between risk factor levels and clinically important outcomes in type 2 diabetes after adjusting for multiple confounders.MethodsWe used retrospective longitudinal data on 246,544 adults with type 2 diabetes from 600 practices in the Clinical Practice Research Datalink, 2006–2012. Proportional hazards regression models quantified the risks of mortality and microvascular or macrovascular events associated with four modifiable biological variables (HbA1c, systolic BP, diastolic BP and total cholesterol), while controlling for important patient and practice covariates.ResultsU-shaped relationships were observed between all-cause mortality and levels of the four biometric risk factors. Lowest risks were associated with HbA1c 7.25–7.75% (56–61 mmol/mol), total cholesterol 3.5–4.5 mmol/l, systolic BP 135–145 mmHg and diastolic BP 82.5–87.5 mmHg. Coronary and stroke mortality related to the four risk factors in a positive, curvilinear way, with the exception of systolic BP, which related to deaths in a U-shape. Macrovascular events showed a positive and curvilinear relationship with HbA1c but a U-shaped relationship with total cholesterol and systolic BP. Microvascular events related to the four risk factors in a curvilinear way: positive for HbA1c and systolic BP but negative for cholesterol and diastolic BP.Conclusions/interpretationWe identified several relationships that support a call for major changes to clinical practice. Most importantly, our results support trial data indicating that normalisation of glucose and BP can lead to poorer outcomes. This makes a strong case for target ranges for these risk factors rather than target levels.

[1]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[2]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[3]  Evangelos Kontopantelis,et al.  Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study , 2012, BMJ quality & safety.

[4]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[5]  S. Wyke,et al.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.

[6]  A B MARTIN,et al.  On a patient-centered approach. , 1960, The American journal of nursing.

[7]  M. Rutter,et al.  Low HbA1c and mortality: causation and confounding , 2012, Diabetologia.

[8]  J. Schafer,et al.  Missing data: our view of the state of the art. , 2002, Psychological methods.

[9]  C. Bartlett,et al.  Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[10]  M. Rutter,et al.  Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. , 2011, European heart journal.

[11]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[12]  M. S. Kirkman,et al.  Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011 .

[13]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[14]  Diane Lacaille,et al.  Systematic Review and Meta-Analysis of Validation Studies on a Diabetes Case Definition from Health Administrative Records , 2013, PloS one.

[15]  S. Silverman,et al.  From randomized controlled trials to observational studies. , 2009, The American journal of medicine.

[16]  C. Torp‐Pedersen,et al.  Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes , 2012, Diabetologia.

[17]  G. Assmann,et al.  The Münster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. , 1997, Circulation.

[18]  R. Heine,et al.  Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study , 2010, The Lancet.

[19]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[20]  Evangelos Kontopantelis,et al.  Relationship between quality of care and choice of clinical computing system: retrospective analysis of family practice performance under the UK's quality and outcomes framework , 2013, BMJ Open.

[21]  André Scheen,et al.  RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient , 2012 .

[22]  Evangelos Kontopantelis,et al.  Withdrawing performance indicators: retrospective analysis of general practice performance under UK Quality and Outcomes Framework , 2014, BMJ : British Medical Journal.

[23]  P. Nilsson Target blood pressure in diabetes patients with hypertension —What is the accumulated evidence in 2011? , 2011, Journal of Zhejiang University SCIENCE B.

[24]  J. Kastelein,et al.  Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. , 2008, Mayo Clinic proceedings.

[25]  E. Braunwald,et al.  Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .

[26]  S. Heymsfield,et al.  Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among Diabetic Patients , 2013, Diabetes Care.

[27]  S. Wild,et al.  External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[28]  D. Reeves,et al.  ClinicalCodes: An Online Clinical Codes Repository to Improve the Validity and Reproducibility of Research Using Electronic Medical Records , 2014, PloS one.

[29]  Michael E. Miller,et al.  Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial , 2014, Diabetes Care.

[30]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[31]  A Rogier T Donders,et al.  Dealing with missing outcome data in randomized trials and observational studies. , 2012, American journal of epidemiology.

[32]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[33]  R. Stevens,et al.  Type and accuracy of sphygmomanometers in primary care: a cross-sectional observational study. , 2011, The British journal of general practice : the journal of the Royal College of General Practitioners.

[34]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[35]  Irene Petersen,et al.  Application of Multiple Imputation using the Two-Fold Fully Conditional Specification Algorithm in Longitudinal Clinical Data , 2014, The Stata journal.

[36]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[37]  D. Cook,et al.  Blood pressure recording bias during a period when the Quality and Outcomes Framework was introduced , 2009, Journal of Human Hypertension.

[38]  T. Manolio,et al.  Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). , 1999, The American journal of cardiology.

[39]  K. Khunti,et al.  Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study , 2012, BMJ : British Medical Journal.

[40]  A. Vaag,et al.  Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials , 2011, BMJ : British Medical Journal.

[41]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.